Filing Details
- Accession Number:
- 0000886163-21-000016
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-01-27 19:04:03
- Reporting Period:
- 2021-01-25
- Accepted Time:
- 2021-01-27 19:04:03
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 886163 | Ligand Pharmaceuticals Inc | LGND | Pharmaceutical Preparations (2834) | 770160744 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1208906 | L John Higgins | 3911 Sorrento Valley Boulevard, Ste 110 San Diego CA 92121 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2021-01-25 | 50,000 | $14.47 | 285,310 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-01-25 | 50,000 | $159.00 | 235,310 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-01-25 | 5,946 | $0.00 | 241,256 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2021-01-25 | 2,845 | $156.01 | 238,411 | No | 4 | F | Direct | |
| Common Stock | Acquisiton | 2021-01-25 | 9,607 | $0.00 | 248,018 | No | 4 | A | Direct | |
| Common Stock | Disposition | 2021-01-25 | 4,596 | $156.01 | 243,422 | No | 4 | F | Direct | |
| Common Stock | Acquisiton | 2021-01-27 | 40,000 | $14.47 | 283,422 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2021-01-27 | 40,000 | $182.00 | 243,422 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2021-01-27 | 30,000 | $21.92 | 273,422 | No | 4 | M | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | A | Direct | |
| No | 4 | F | Direct | |
| No | 4 | A | Direct | |
| No | 4 | F | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2021-01-25 | 50,000 | $0.00 | 50,000 | $14.47 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2021-01-27 | 40,000 | $0.00 | 40,000 | $14.47 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2021-01-27 | 30,000 | $0.00 | 30,000 | $21.92 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 109,000 | 2022-02-09 | No | 4 | M | Direct | |
| 69,000 | 2022-02-09 | No | 4 | M | Direct | |
| 65,616 | 2023-02-15 | No | 4 | M | Direct |
Footnotes
- The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on December 10, 2020, in accordance with Rule 10b5-1.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $150.00 to $165.00, inclusive. The reporting person undertakes to provide, upon request to the Securities Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 05/30/2018 and were eligible to vest based on the Issuer achievement of certain performance objectives during the three-year performance period ending December 31, 2020. On January 25, 2021, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares.
- Represents shares withheld by the Issuer in payment of the tax liability arising in connection with the settlement of the PSUs.
- Represents the number of shares of common stock issued upon the vesting of performance stock units (PSUs). Each PSU represented a contingent right to receive one share of the Issuer common stock. The PSUs were originally granted on 05/29/2019 and were eligible to vest based on the Issuer achievement of certain performance objectives during the two-year performance period ending December 31, 2020. On January 25, 2021, the Compensation Committee of the Board of Directors of the Issuer certified the Issuer achievement relative to the applicable performance objectives and approved the vesting of the PSUs with respect to these shares.
- Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/09/12.
- Grant to reporting person of options, exercisable over a 4-year period measured from the date of grant, 12-1/2% after six months, then 1/48th of the Option Shares per month thereafter. The date of grant was 02/15/13.
Billionaire Hedge Funds
